** Shares of medtech firm Glaukos GKOS.N fall 11.2% to $139.7 premarket
** Co on Thursday posted Q4 net loss of $22.2 mln, vs Wall Street estimate of $20.8 mln loss, as per data compiled by LSEG
** GKOS reported Q4 revenue of $105.5 mln, vs est. of $100.7 mln
** Co forecast 2025 sales in the range of $475 million to $485 million compared with expectation of $479.8 mln
** GKOS's lead product is the iStent inject W, a device used to treat glaucoma, an eye condition that damages the optic nerve
** Stock has risen 75.7% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。